KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to 268.63%.

  • Nektar Therapeutics' EBITDA Margin fell 1262700.0% to 268.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 156.69%, marking a year-over-year increase of 76400.0%. This contributed to the annual value of 106.88% for FY2024, which is 1857100.0% up from last year.
  • Per Nektar Therapeutics' latest filing, its EBITDA Margin stood at 268.63% for Q3 2025, which was down 1262700.0% from 324.21% recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' EBITDA Margin ranged from a high of 49.18% in Q4 2024 and a low of 708.07% during Q2 2022
  • Its 5-year average for EBITDA Margin is 320.47%, with a median of 268.63% in 2025.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -3190600bps in 2022, then soared by 4612300bps in 2023.
  • Quarter analysis of 5 years shows Nektar Therapeutics' EBITDA Margin stood at 451.48% in 2021, then surged by 47bps to 238.25% in 2022, then skyrocketed by 41bps to 140.3% in 2023, then soared by 135bps to 49.18% in 2024, then crashed by -646bps to 268.63% in 2025.
  • Its last three reported values are 268.63% in Q3 2025, 324.21% for Q2 2025, and 425.76% during Q1 2025.